Pharmaceutical company Perrigo Co., under pressure from an investor to focus on over-the-counter drugs, reached a deal worth up to $2.85 billion to sell royalties from its multiple-sclerosis drug Tysabri to pharmaceutical investor Royalty Pharma. Dublin-based Perrigo also disclosed on Monday plans to eliminate about 750 positions and said it’s reviewing its active pharmaceutical-ingredients business and continuing an “enhanced...

Source: Wall Street Journal February 28, 2017 00:27 UTC